viernes, 30 de mayo de 2008

Las propiedades del NADH


Cada célula viva contiene NADH, una coenzima critica en la producción de energía: Las células que necesitan más de este aporte de energía son las del cerebro y músculo.

Como el Coenzima Q10, el NADH está involucrado en la síntesis de ATP, la primera fuente intracelular de energía.

El NADH se encuentra presente en muchos de los alimentos que comemos, pero el procesado, cocinado, y los ácidos del estómago, lo destruye.

El NADH mejora la salud mental y física. Mejora la producción de neurotransmisores como la dopamina (un mensajero químico para la memoria a corto plazo, tono muscular, movimientos y reacciones físicas espontáneas, así como la liberación de hormona de crecimiento). Sin dopamina los músculos se vuelven flojos, el ejemplo ocurre con la enfermedad de Parkinson dónde el desorden está causado en parte por la destrucción de las células del cerebro que sintetizan dopamina.
Por otro lado si mejoran los niveles de dopamina y de Noradrenalina, pueden mejorar los signos de depresión.
Muchos son los estudios que demuestran la mejora a nivel del rendimiento físico y de la fatiga en aquellos pacientes con fatiga crónica.

CELLERGIE está científicamente probado como:
• Uno de los antioxidantes más potentes
• Puede mejorar rendimiento cerebral
• Puede dar mayor aporte de oxígeno a las células
• Puede proteger a la célula de funciones importantes
• Produce energía y agua en las células
• Repara el daño producido por las células envejecidas de la piel
Consejo de uso: Tomar 1-2 tabletas CELLERGIE cada mañana con un estomago vació, 30 minutos antes de una comida, con sólo medio vaso de agua.
La efectividad óptima se muestra después de 4 semanas de uso continuado.


En la tienda disponemos de

Cellergie es la formula original de la única forma estabilizada de N.A.D.H patentada.
Completamente natural, sin conservantes, colores o aromas artificiales.
Auténtica producida por el Prof. Birkmayer.

Cellergie (NADH) en tabletas de 7.5 mg

Cellergie (NADH) serum para la piel

Coenzima Q10
muy interesante combinarlo con NADH tabletas sobre todo cuando el objetivo que se busque es mejorar la fatiga.
Bibiliografía
A) Actions of NADH

1. “NADH-supplementation decreased pinacidil-primed I K(ATP) in ventricular cardiomyocytes by increasing intracellular ATP” Pelzmann B, Hallström S, Schaffer P, Lang P,Nadlinger K, Birkmayer GD, Vrecko C, Reibnegger G and Koidl B. Brit. J. Pharm. 2003 139, 749-754.

2. “The Reduced Coenzyme Nicotinamide Adenine Dinucleotide (NADH) repairs DNA damage of PC12 cells induced by doxorubicin” Zhang JR, Vrecko K, Nadlinger K, Storga D, Birkmayer GD, Reibnegger G J.Tumor Marker Oncol. 1998; 13, 5-17.

3. “X-ray induced LO2 cells damage rescued by new antioxidant NADH “, Fa-Quan L, Zhang JR. World J. Gastorenterol. 2003, 9(8): 1781-1785.

4. “The Reduced Coenzyme Nicotinamide Adenine Dinucleotide (NADH) rescues PC 12 cells from Apoptosis” Zhang JR,.Vrecko K,.Nadlinger K.. Storga D,.Birkmayer GD, Reibnegger G,J.Tumor Marker Oncol.1998; 13(3): 11-24.

5. “The Cytoprotection of Nicotinamide Adenine Dinucleotide (NADH) by the Mitochondrial Regulation Mechanism” Meng X, hang JR, Hui SSC, J. Tumor Marker Oncol. 1998; 17: 167 – 174.
6. "The antioxidative capacity of ENADA®-NADH in humans” Reibnegger G, Greilberger J, Juergens G. and Oettl K.J.Tumor Marker Oncol. 2003; 18, 37-41.

7. “Oral NADH effects blood pressure,lipid peroxidation and lipid profile in spontaneously hypertensive rats.” Busheri N,Taylor J,Lieberman S,Mirdamadi-Zonosi N,Birkmayer G,Preuss HG, Geriat.Nephrol.Urol. 1998;18(2) 5-100.

8. „Influence of reduced Nicotinamide Adenine Dinucleotide (NADH) on the production of Interleukin-6 by peripheral human blood leucocytes” Nadlinger K, Birkmayer J, Gebauer F , Kunze R, Neuroimmunomodulation, 2002; 9: 203 – 208.

9. “NADH stimulates endogenous dopamine biosynthesis by enhancing the recycling of tetrahydrobiopterin in rat phaechromocytoma cells.” Vrecko K, Storga D, Birkmayer GD, Möller R, Tarfeit E, Horejsi R, Reibnegger G, Biochimica et Biophysica Acta 1997; 1361: 59-65.

10. ”Effects of acute and chronic NADH Administration on Peripheral and Central Norepinenphrine and Dopamine Synthesis in the Rat.” Gardier AM Birkmayer Institute for Parkinson Therapy, Internal Lab Report No. 94070401.

11. “NADH:sensor of blood flow in brain, muscle and other tissues” Ido Y.,Chang K,Woosley TA Willimanson JR FASEB, 2001; 15: 1419- 1421.

12. “Reduced nicotinamide nucleotides prevent nitration of tyrosine hydroxylase by peroxinitrite.” Kuhn DM, Geddes TJ. Brain Research 2002; 933: 85-89.

13. “NAD+ dependent repair of damaged DNA by human cell extracts.” Satoh MS, Pirier GG, Lindahl T. Biol. Chem. 1993; 268; 8: 5480-5487.

(B) Stability, Bioavailablity and Safety of NADH
14. “Stable, ingestable and absorbable NADH and NADPH therapeutic compositions,” Birkmayer JGD., United States Patent No. 5.332.727, 1994.

15. “Stable, ingestable and absorbable NADH and NADPH therapeutic compositions,” Birkmayer JGD., European Patent EP 0 697859, 1995.

16. “Investigational New drug Application Birmadil™ Tablets 5mg containing reduced ß-nicotinamide adeninie dinucleotide for Treatment of Dementia of the Alzheimer’s Type” Birkmayer Pharmaceuticals: IND Number 49,766, 1996.

17. “Bioavailability of reduced nicotinamide-adenine-dinucleotide (NADH) in the central nervous system of the anaethesized rat measured by laser-induced fluorescence spectroscopy”. Rex A, Hentschke MP, Fink H, Pharmacol.Toxicol. 2002; 90: 220 -228.

18. “Zur Entwicklung von stabilen Arzneiformen des Coenzyms NADH für die perorale und parenterale Applikation“. Mattern C. Ph.D. Dissertation Humboldt Universität , Berlin, 1996.

19. „Untersuchungen zur Pharmakokinetik von NADH in vivo und in vitro.“ Kappes K. Digitale Dissertation, FU Berlin 2005. ISBN 3-886664-054-4.

20. “On the Safety of Reduced Nicotinamide Adenine Nucleotide (NADH)” Birkmayer JGD, Nadlinger K, Hallström S. Journal Environmental Pathology, Toxicology and Oncology 2004; 23: 179-194.

21. “Safety of stabilized, orally absorbable, reduced nicotinamide adenine dinucleotide (NADH): A 26-week oral tablet administration of ENADA®/NADH for chronic toxicity study in rats” Birkmayer JGD, Nadlinger K. Drugs experimental clinical Research 2002; 28: 185-182.

(C) Applications and Beneficial Effects of NADH

Parkinson’s Disease:
22. “Nicotinamide adenine dinucleotide (NADH) – a new therapeutic approach to Parkinson’s disease: Comparison of oral and parenteral application” Birkmayer JGD, Vrecko C, Volc D, Birkmayer W, Acta Neurol Scand. 1993; 87: 32-35.


23. “Stimulation of the endogenous L-dopa biosynthesis – a new principle for the therapy of Parkinson’s disease: the clinical effect of nicotinamide adenine dinucleotide (NADH) and nicotinamide adenine dinucleotidephosphate (NADPH)” Birkmayer JGD, Birkmayer W. Acta Neurol Scan. 1989; 126:183-187.

24. “Stimulation of dopamine biosynthesis in culture PC12 pheochromocytoma cells by the coenzyme nicotinamide adenine dinucleotide (NADH)” Vrecko K,Birkmayer JGD, Krainz J. J.Neural.Transm. 1993; 5: 147-156.

Depression

25. “ The reduced nicotinamide adenine dinucleotide (NADH) as biological antidepressive agent. Experience with 205 patients” Birkmayer JGD, Birkmayer W, New trends in Clinical Neuropharmacology 1991; 5: 75-86.

26. “ Antidepressant-like effect of nicotinamide adenine dinucleotide in the forced swim test in rats.” Rex A, Schickert R, Fink H Pharmacology, Biochemistry and Behaviour 2004; 77: 303-307.

Chronic Fatigue

27. “The therapeutic effect of NADH in patients with Chronic Fatigue Syndrome” Forsyth L,Preuss. H,Carneiro ML, Chiazze R, Birkmayer GD, Bellanti J; Ann.Allergy Asthma and Immunol., 199.9; 82: 185-191.

28. “Functional Herbal Medicines & Dietary Supplements” Mertens G, Nicholas Hall & Company, 2000; S.17-23.

29. “Die Wirkung von oralem NADH bei Symptomen des Chronischen Müdigkeitssyndroms“
Birkmayer JGD, Journal Orthomolekulare Medizin, 1999; 2: 107-116.

30. “ NADH improves symptoms of patients with chronic fatigue syndrome”
Birkmayer JGD, The Original Internist; 1999; 6: 6-8.

Dementia of the Alzheimer Type
31. “Treatment of Alzheimer’s Disease with stabilized oral Nicotinamide Adenine Dinucleotide: A randomized, double-blind study” Demarin V, Podobnik-Sarkanji S, Storga-Tomic D, Kay G, Drugs exptl. Clin.Res. 2004; 30: 27-337.

32. “Improvement of Verbal Fluency in Alzheimer’s Disease After NADH Treatment” Demarin V,Storga-Tomic D, Bosnar-Puretic M, Martinic-Popovic I, Birkmayer J, Proceedings 7th Congress European Society for Clinical Neuropharmacology ed: Medimond 2004; 41-45.
Cancer

33. “NADH in Cancer Prevention and Therapy” in Phytopharmaceuticals in Cancer Chemoprevention” Birkmayer JGD, Zhang JR, ed. Bagchi D, Preuss H, CRC Press 2005; chapter 33, 541- 554.
Physical and mental Performance

34. „Einfluss einer NADH Supplementation auf die muskuläre Energiebereitstellung beim Menschen” „Influence of NADH supplementation for the muscular energy supply in humans“ Grathwohl D, Klann M, Müller HM, Schlachter H und Berg A.Deutsche Zeitschrift für Sportmedizin, 11/2000.

35. “ENADAlert® improves physical and mental performance in highly conditioned athletes” Birkmayer GD and Nadlinger K. J. Tum.Marker Oncol. 2003; 18: 51-55.

36. “Extracellular metabolization of NADH by blood cells correlated with intracellular ATP levels” Nadlinger K,Westerthaler W, Storga-Tomic D, Birkmayer JGD Biophys. Biochim Acta 2002; 1573: 177-182.

Jet Lag and Sleep Deprivation

37. “ Assesssing the Efficacy of Pharmaceuticals and Nutraceuticals as Countermeasures for Jet Lag” Virre ES, Kay GG, Abstr. Commun. 7th Conference Int. Society Travel Medicine 2001; FC06.03.

38. “ Stabilisiertes NADH (ENADA) verbessert die durch Jet Lag reduzierte Hirnleistung“ (Stabilized NADH as Counter Measure for Jet Lag) Birkmayer JGD, Kay GG, Virre ES, Wiener Med.Wochenschr. 2002; 17/18: 450-454.

39. “Stabilized NADH (ENADA) as Counter-Measure Jet Lag and Sleep Deprivation” Kay GG, Virre ES, Moline M J. Tumor Marker Oncol. 2001; 16 : 124-125.

40. „Stabilisiertes NADH (ENADA) verbessert die Symptome von Schlafentzug und Jet Lag“. Birkmayer JGD, Med. Welt 2001; 7: 61.

41. “NAD+ and NADH in brain functions, brain diseases and brain aging.” Ying W., Front. Biosci. 2007; 12:1863 – 88.

42. “NAD+ and NADH in cellular functions and cell death.” Weihai Ying, Frontiers in Bioscience 2006; 11, 3129-3148.
Menopause

43. “ NADH – neue Wege in der Behandlung des klimakterischen Syndroms“ Friedrich F, Nadlinger K, Birkmayer JGD, Friedrich F, J. Menopause 2006, 10:10-12.

44. „Coenzym-1 (N.A.D.H.) verbessert die Symptome des klimakterischen Syndroms“ JGD Birkmayer, Geburtsh Frauenheilk 2006; 67

Anti-Aging

45. “Coenzym 1 (N.A.D.H.): A Proven Anti-Aging Substance” Birkmayer JGD, Abstr.Comm. 1st European Congress on Anti-Aging Medicine .Oct. 18 – 21, 2006 Vienna, Austria

46. „Coenzym-1 (NADH) – Eine wissenschaftlich bewiesene Anti-Aging- Substanz“ Birkmayer JGD, Prevention and anti aging 2006 340-348.

47. „Method of prolonging the Life-span of Living Cells using NADH, NADPH and ADP-Ribose” Birkmayer JGD, Nadlinger K, Hallstöm S, Westerthaler W, US-Patent Pub.No. US 2004 / 0126751

Cosmetic and Dermatological Applications

48. “NADH and NADPH therapeutic Agents for nasal , sublingual, rectal and dermal administration” Birkmayer JGD, United States Patent Nr. 5,952.312 1999.

49. „ Ointment Preparation containing NADH in Teleangiectasis“ Augustin M, Zschocke I, Final Biometric Report, Universitäts Hautklinik, Freiburg, Germany Okt. 2000.

50. „ENACHI Skin Serum – An innovative unique cosmetic product based on ENADA™-NADH”
Birkmayer JGD, Nutraceuticals Now 2005; 44-45.

51. “NADH- The energizing Coenzyme” Birkmayer George D. Keats Good Health, Keats Publishing ,Inc. 1998.